Changes in pharma marketing will be profound with the advent of technology. Digital marketing will allow pharma marketers to engage the customer in very meaningful ways which were not always possible through the work of sales reps. While sales reps are important in the scheme of things, they are but one channel. In-clinic time with […]Read More Don’t make it feel like it’s marketing
The first time I heard the term ‘digital economy’ in the medical context, it was from a reputed doctor who was a co-panelist and speaker at a company town hall event on digital marketing. It did not surprise me one bit that the doctor knew more about the digital economy than most of the pharma […]Read More The Digital Economy
Recently, I did an interview with MedicinMan on digital technology, its applications in health care and its adoption by the pharmaceutical industry. The interview, published earlier in MedicinMan, is reproduced below: Q : What exactly is digital? Digital technology is an amazing system whereby information (words and images) are stored in the form of code. This […]Read More Slaying the Digital beast
People talk a lot about “freedom” these days. Be it freedom from colonial rule or the freedom of expression, the freedom of the Internet, the freedom to watch porn, to have consensual sex in beach-side resorts or the freedom to marry irrespective of faith. At the root of each of these passionate beliefs is the […]Read More Health and the freedom of choice
The post-9/11 world was a difficult place for both political and business leaders to adjust to. As power structures in the world shifted, the developed world struggled to retain political and economic control in a scenario sometimes described as the ‘decline of the West’. Capital fled these risky markets in search of those that were […]Read More Will pharma forsake emerging markets?
India’s economy is performing poorly, at least compared to its relative dynamism just a few years ago. With a general election to be concluded by the end of May 2014, many are looking to the country’s next government to break India out of its economic doldrums. Pre-poll surveys (whether you like them or not) have […]Read More What can the pharmaceutical industry expect from the new government?
Pharma Selling Model must Adapt (Listen to the audio file (5:03) by clicking on the link) Worldwide, medical research and health care philosophy is undergoing fundamental shifts. The first is a fundamental and significant shift in healthcare philosophy and medical research – from a world in which we “react” to disease and illness after it has […]Read More Pharma Selling Model must Adapt
Earlier this month, a Parliamentary Standing Committee tabled its recommendations on Foreign Direct Investment (FDI) in the pharmaceuticals sector. Surprisingly for a country that recently prided itself for unshackling its economy and pushing pro-growth reforms, the Committee recommended a blanket ban on FDI in brownfield projects which means it doesn’t want foreign pharmaceutical companies to […]Read More FDI in Pharma – Fools (can) Destroy India
What if clinical trials don’t happen in India? Indian patients will continue to be treated with existing standard of stagnating care. The world would have moved on to better medicines buoyed by innovation. But Indian patients will need to be excluded from this wave of change for the better. The Drugs Controller General of India (DCGI)’s […]Read More What if clinical trials don’t happen in India?
A variety of factors such as growing population and economy, increasing life expectancy, expanding middle class, higher income levels, rise in incidence of diseases, increased government outlays and better awareness about health are expected to make India’s health care a US$ 280 billion industry by 2020. Despite this growth, health care delivery and services in […]Read More India’s Decision to Invoke Compulsory Licensing